Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nalfurafine - Toray

Drug Profile

Nalfurafine - Toray

Alternative Names: AC-820; MT-9938; Nalfurafine hydrochloride; Nopicor; REMITCH; REMITCHTM; SSS-33; TRK-820; Winfuran

Latest Information Update: 28 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Toray
  • Developer Fresenius Medical Care; Immunis; Japan Tobacco; Maruho; Shenyang Sunshine Pharmaceutical; SK Chemicals; Toray; Torii Pharmaceutical
  • Class Antipruritics; Morphinans; Opioid analgesics; Small molecules; Spiro compounds
  • Mechanism of Action Opioid kappa receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pruritus
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pruritus
  • Preclinical Sarcopenia
  • Discontinued Atopic dermatitis; Cancer pain; Neuropathic pain

Most Recent Events

  • 22 May 2024 Nalfurafine licensed to Immunis for the treatment of Sarcopenia
  • 22 May 2024 Preclinical trials in Sarcopenia in USA (unspecified route), prior to May 2024
  • 22 May 2024 Immunis plans a phase II trial in Sarcopenia
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top